Stockscreener 앱 받기
1.68
6.67%
-0.12
시간 외 거래:
1.74
0.06
+3.57%
전일 마감가:
$1.80
열려 있는:
$1.82
하루 거래량:
324.43K
Relative Volume:
1.03
시가총액:
$47.75M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.29%
1개월 성능:
-17.24%
6개월 성능:
-83.15%
1년 성능:
+0.00%
1일 변동 폭
$1.6705
$1.90
1주일 범위
$1.6705
$2.15
52주 변동 폭
$1.6705
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
명칭
Artiva Biotherapeutics Inc
전화
(858) 267-4467
주소
5505 MOREHOUSE DRIVE, SAN DIEGO
ARTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
1.68 | 47.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 개시 | Jefferies | Buy |
| 2024-08-13 | 개시 | Needham | Buy |
| 2024-08-13 | 개시 | TD Cowen | Buy |
| 2024-08-13 | 개시 | Wedbush | Outperform |
모두보기
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Bank of America Corp DE Sells 7,001 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Brokers Set Expectations for ARTV Q2 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by HC Wainwright to Buy Rating - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at HC Wainwright - Defense World
Brokers Offer Predictions for ARTV FY2026 Earnings - Defense World
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside - TipRanks
Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright - TipRanks
NK Cell Therapy Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
Deutsche Bank AG Takes Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Bought by BNP Paribas Financial Markets - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Analysts - Defense World
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Reviewing Bio-Techne (NASDAQ:TECH) and Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price - Defense World
Research Analysts Offer Predictions for ARTV FY2025 Earnings - Defense World
Artiva Biotherapeutics Reports Q1 2025 Progress - MSN
Artiva Biotherapeutics announces new, long-term data for AlloNK combination - TipRanks
Artiva Biotherapeutics Reports Promising Phase 1/2 Data for AlloNK® in Combination with Rituximab for Heavily Pretreated B-cell Non-Hodgkin Lymphoma Patients - Nasdaq
Artiva reports promising AlloNK therapy results in B-NHL study - Investing.com
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewswire
Artiva Biotherapeutics, Inc. Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK®? in Combination with Rituximab in Patients with B-Cell-Cell- Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - marketscreener.com
Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating - TipRanks
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance - TipRanks
Artiva Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Acquires 26,893 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Acquired by Geode Capital Management LLC - Defense World
Artiva Biotherapeutics Announces Promising Data for AlloNK® + Rituximab in B-cell Driven Diseases Ahead of ASGCT 28th Annual Meeting - Nasdaq
Artiva Biotherapeutics to Present Longer-term Phase 1/2 - GlobeNewswire
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - Yahoo Finance
NK Cell Therapy Therapeutics Market Size in 7MM is expected - openPR.com
Norges Bank Buys New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Norges Bank Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - The AM Reporter
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support - TipRanks
Artiva Biotherapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Names New Chief Medical Officer - marketscreener.com
Artiva Biotherapeutics names new Chief Medical Officer - Investing.com Australia
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday SessionAgilon Health (NYSE:AGL), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics (ARTV) – Investment Analysts’ Recent Ratings Changes - Defense World
12 Health Care Stocks Moving In Monday's Intraday SessionAditxt (NASDAQ:ADTX), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Inc (ARTV) 재무 분석
Artiva Biotherapeutics Inc (ARTV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Artiva Biotherapeutics Inc 주식 (ARTV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
833,333 |
9,999,996 |
1,182,054 |
| venBio Global Strategic Fund I | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,936,637 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
1,666,666 |
19,999,992 |
3,306,900 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,260,512 |
| Huh Yong-Jun | Director |
Jul 22 '24 |
Buy |
12.00 |
2,083,332 |
24,999,984 |
3,306,900 |
2.13%
1.01%
자본화:
|
볼륨(24시간):